Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Braz. J. Pharm. Sci. (Online) ; 58: e20139, 2022. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1403755

RESUMEN

Abstract Compounding pharmacies play an important role not only in compounding personalized formulations, but also preparing drugs at the same concentration and dosage as those from commercial manufacturers. The excipients used in compounding are generally standardized for many drugs, however they do not consider the intrinsic properties, such as the poor water solubility, of each substance. The excipient performance of commercially available compounded furosemide capsules in 7 compounding pharmacies from Manaus was evaluated and compared them to the performance of the reference medicinal product (Lasix® tablets) and 2 batches of capsules made in-house (T2 and T4) with a standardized excipient. All batches were subjected to tests for weight variation, assay, uniformity of dosage units, disintegration and dissolution profile. Of the 7 different compound formulas acquired in the compounding pharmacies, only 2 passed all tests. Most formulas passed the tests for weight determination, disintegration time and assay, however batches from 2 establishments failed in regards to the uniformity of the content and 5 batches failed the dissolution test. The reference medicinal product was approved in all tests, as were the T2 capsules made in-house with drug-excipient ratio 1:2. These results confirm the importance of the excipient composition, especially for poorly soluble drugs.


Asunto(s)
Comprimidos/efectos adversos , Cápsulas/análisis , Excipientes/análisis , Furosemida/análisis , Farmacias/normas , Control de Calidad , Preparaciones Farmacéuticas/clasificación , Buenas Prácticas de Manipulación , Dosificación , Disolución
2.
São Paulo; s.n; 2005. 234,xxix p. ilus, tab, graf.
Tesis en Portugués | LILACS | ID: lil-425843

RESUMEN

Leishmaniose e doença de Chagas são parasitoses endêmicas causadas, respectivamente, pelos protozoários Leishmania spp. e Trypanosoma cruzi. Ante à escassez de quimioterápicos, à elevada toxicidade dos fármacos disponíveis e à baixa eficácia destes no combate às formas intracelulares, replicantes, dos parasitos há necessidades de buscar novas alternativas quimioterápicas. A atividade tripanomicida do hidroximetilnitrofural, base de Mannich do nitrofural, já era conhecida. O presente trabalho mostra que este derivado também apresenta atividade leishmanicida, quando ensaiado em formas promastigotas de L. amazonensis, L. chagasi e L. baziliensis. Com o objetivo de obter pró-fármacos potencialmente ativos em doença de Chagas e leishmanioses visceral e mucocutânea, planejaram-se e foram sintetizados derivados hidrossolúveis de hidroximetilnitrofural e quitosana, polissacarídeo que apresenta, também, atividade imunomoduladora...


Asunto(s)
Enfermedad de Chagas , Drogas en Investigación , Leishmaniasis , Nitrofurazona , Polisacáridos , Resistencia a Medicamentos , Química Farmacéutica , Espectroscopía de Resonancia Magnética/métodos , Nitrocompuestos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA